This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

SaddleBrooke Freethinkers are proud to have Professor Lalitha Madhavan MD, PhD, in the Department of Neurology at the University of Arizona College of Medicine speak on “'Disease-in-a-dish' and ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

Researchers have developed an AI system that predicts chemical compounds capable of targeting two proteins simultaneously, ...

Smartwatches gather vast amounts of data about our physiology. Now their technology is being harnessed like never before.

Cheryl Daste mirrors a motion from instructors Kelly Haber and April Dayok at the Wednesday dance class at the Jewish Community Center in New Orleans for people affected by Parkinson’s disease.

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

A new study shows that a common glaucoma drug cleared tau build-up and reduced signs of neurodegenerative disease in zebrafish and mice.

Most Americans (about two-thirds) will experience some form of cognitive decline by the age of 70, research shows. (The ...